Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
09 mai 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment”
27 avr. 2023 09h15 HE
|
Atossa Therapeutics, Inc.
Virtual webinar scheduled for Thursday, May 4 at 8:00 am pacific / 11:00 am easternMeet with Atossa’s Founder and CEO, Steven Quay, M.D., Ph.D.Event is open to the public – registration available at...
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update
22 mars 2023 16h05 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
21 mars 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE and SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of...
Atossa to Present at the Sidoti Small-Cap Virtual Conference
15 mars 2023 09h25 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
23 févr. 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen
13 févr. 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Issues Letter to Shareholders
25 janv. 2023 09h15 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant...
Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations
07 déc. 2022 08h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical...
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
07 nov. 2022 16h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on...